This Article Full Text Full Text (PDF) Submit a response to this article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                            What's this?

"Off-Label" Indications for Oncology Drug Use and Drug Compendia: History and Current Status

Amid oncologists' continuing concerns over Medicare coverage of new uses of anticancer medications, one of the authoritative drug compendia is undergoing administrative and editorial changes, and a new oncology drug compendium has been partially released.

Michael Soares, RPh

Medicare must cover off-label uses of anticancer chemotherapeutic regimens if they are supported by a citation in at least one of the following compendia: American Hospital Formulary Service Drug Information (AHFS DI), United States Pharmacopoeia Drug Information (USP DI) or American Medical Association Drug Evaluations.³ The latter was merged into USP DI in 1996 and is now . . . [Click for More]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. S. Kramer, K. L. Hagerty, M. R. Somerfield, and P. Schellhammer Reply to P.C. Walsh J. Clin. Oncol., July 10, 2009; 27(20): e23 - e23. [Full Text] [PDF]

				M. R. Gillick Controlling Off-Label Medication Use Ann Intern Med, March 3, 2009; 150(5): 344 - 347. [Abstract] [Full Text] [PDF]